Orfiril 300 (Sodium Valproate)

Sodium valproate, the active ingredient in Orfiril 300, is an antiepileptic presented as a tablet for oral use. It is used to treat various seizure types and is prescribed for patients requiring long‑term seizure control. GNH USA supplies Orfiril 300 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Orfiril 300 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Orfiril 300 is an antiepileptic medication that acts on neuronal excitability in the central nervous system.

- Generalised tonic‑clonic seizures: helps reduce the frequency and severity of seizures. - Absence seizures: decreases the number of brief loss‑of‑awareness episodes. - Myoclonic seizures: lowers the occurrence of sudden muscle jerks. - Lennox‑Gastaut syndrome: contributes to overall seizure control in this severe epilepsy syndrome. - Bipolar disorder (off‑label): may be used as a mood stabiliser under specialist supervision.

Side effects of sodium valproate are reported across a range of frequencies.

Common Side Effects: - Nausea and vomiting - Tremor - Weight gain - Hair loss - Drowsiness - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver injury - Pancreatitis - Thrombocytopenia - Hyperammonemia - Stevens‑Johnson syndrome - Fatal brain‑stem encephalopathy

When using Orfiril 300, several precautions should be observed to ensure safety and effectiveness.

- Liver function monitoring: regular blood tests are required to detect hepatic impairment. - Platelet count monitoring: periodic checks help identify thrombocytopenia. - Pregnancy considerations: val‑t‑c    t   t  t  t  r   - Drug‑induced pancrepan   t  t. - Renal  t  t. - Store at  t  t. - Store below 25°C: keep in the original pack, protect from moisture.

Orfiril 300 may interact with several other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): -  t  t  t. -   t \